The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, New York 10032.

Because physicians have traditionally considered heart failure to be a hemodynamic disorder, they have described the syndrome of heart failure using hemodynamic concepts and have designed treatment strategies to correct the hemodynamic derangements of the disease. However, although hemodynamic abnormalities may explain the symptoms of heart failure, they are not sufficient to explain the progression of heart failure and, ultimately, the death of the patient. Therapeutic interventions may improve the hemodynamic status of patients but adversely affect their long-term outcome. These findings have raised questions about the validity of the hemodynamic hypothesis and suggest that alternative mechanisms must play a primary role in advancing the disease process. Several lines of evidence suggest that neurohormonal mechanisms play a central role in the progression of heart failure. Activation of the sympathetic nervous system and renin-angiotensin system exerts a direct deleterious effect on the heart that is independent of the hemodynamic actions of these endogenous mechanisms. Therapeutic interventions that block the effects of these neurohormonal systems favorably alter the natural history of heart failure, and such benefits cannot be explained by the effect of these treatments on cardiac contractility and ejection fraction. Conversely, pharmacologic agents that adversely influence neurohormonal systems in heart failure may increase cardiovascular morbidity and mortality, even though they exert favorable hemodynamic effects. These observations support the formulation of a neurohormonal hypothesis of heart failure and provide the basis for the development of novel therapeutic strategies in the next decade.

This article has been cited by other articles:

				M. Klapholz {beta}-Blocker Use for the Stages of Heart Failure Mayo Clin. Proc., August 1, 2009; 84(8): 718 - 729. [Abstract] [Full Text] [PDF]

				S. Somekawa, K. Imagawa, N. Naya, Y. Takemoto, K. Onoue, S. Okayama, Y. Takeda, H. Kawata, M. Horii, T. Nakajima, et al. Regulation of Aldosterone and Cortisol Production by the Transcriptional Repressor Neuron Restrictive Silencer Factor Endocrinology, July 1, 2009; 150(7): 3110 - 3117. [Abstract] [Full Text] [PDF]

				A. Boccanelli, G. F. Mureddu, G. Cacciatore, F. Clemenza, A. Di Lenarda, A. Gavazzi, M. Porcu, R. Latini, D. Lucci, A. P. Maggioni, et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results Eur J Heart Fail, January 1, 2009; 11(1): 68 - 76. [Abstract] [Full Text] [PDF]

				M. Landolina, M. Gasparini, M. Lunati, M. Santini, R. Rordorf, A. Vincenti, P. Diotallevi, A. S. Montenero, C. Bonanno, T. De Santo, et al. Heart rate variability monitored by the implanted device predicts response to CRT and long-term clinical outcome in patients with advanced heart failure Eur J Heart Fail, November 1, 2008; 10(11): 1073 - 1079. [Abstract] [Full Text] [PDF]

				B. Olshansky, H. N. Sabbah, P. J. Hauptman, and W. S. Colucci Parasympathetic Nervous System and Heart Failure: Pathophysiology and Potential Implications for Therapy Circulation, August 19, 2008; 118(8): 863 - 871. [Full Text] [PDF]

				B. Bishara, H. Shiekh, T. Karram, I. Rubinstein, Z. S. Azzam, N. Abu-Saleh, S. Nitecki, J. Winaver, A. Hoffman, and Z. A. Abassi Effects of Novel Vasopressin Receptor Antagonists on Renal Function and Cardiac Hypertrophy in Rats with Experimental Congestive Heart Failure J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 414 - 422. [Abstract] [Full Text] [PDF]

				S.-G. Wei, Y. Yu, Z.-H. Zhang, R. M. Weiss, and R. B. Felder Angiotensin II-Triggered p44/42 Mitogen-Activated Protein Kinase Mediates Sympathetic Excitation in Heart Failure Rats Hypertension, August 1, 2008; 52(2): 342 - 350. [Abstract] [Full Text] [PDF]

				M. Schou, C. Torp-Pedersen, F. Gustafsson, J. Abdulla, and L. Kober Wall motion index, estimated glomerular filtration rate and mortality risk in patients with heart failure or myocardial infarction: A pooled analysis of 18,010 patients Eur J Heart Fail, July 1, 2008; 10(7): 682 - 688. [Abstract] [Full Text] [PDF]

				V. J Colucci and B. D Berry Heart Failure Worsening and Exacerbation After Venlafaxine and Duloxetine Therapy Ann. Pharmacother., June 1, 2008; 42(6): 882 - 887. [Abstract] [Full Text] [PDF]

				A. Gourine, S. I. Bondar, K. M. Spyer, and A. V. Gourine Beneficial Effect of the Central Nervous System {beta}-Adrenoceptor Blockade on the Failing Heart Circ. Res., March 28, 2008; 102(6): 633 - 636. [Abstract] [Full Text] [PDF]

				M. Kurzyna and A. Torbicki Neurohormonal modulation in right ventricular failure Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H35 - H40. [Abstract] [Full Text] [PDF]

				S. B. Liggett, R. J. Kelly, R. R. Parekh, S. J. Matkovich, B. J. Benner, H. S. Hahn, F. M. Syed, A. S. Galvez, K. L. Case, N. McGuire, et al. A functional polymorphism of the G{alpha}q (GNAQ) gene is associated with accelerated mortality in African-American heart failure Hum. Mol. Genet., November 15, 2007; 16(22): 2740 - 2750. [Abstract] [Full Text] [PDF]

				D. Seo and J. M. Hare The Transforming Growth Factor-{beta}/Smad3 Pathway: Coming of Age as a Key Participant in Cardiac Remodeling Circulation, November 6, 2007; 116(19): 2096 - 2098. [Full Text] [PDF]

				C. Vassalle, M. G. Andreassi, C. Prontera, M. Fontana, L. Zyw, C. Passino, and M. Emdin Influence of ScaI and Natriuretic Peptide (NP) Clearance Receptor Polymorphisms of the NP System on NP Concentration in Chronic Heart Failure Clin. Chem., November 1, 2007; 53(11): 1886 - 1890. [Abstract] [Full Text] [PDF]

				H. Kioka, T. Yamada, T. Mine, T. Morita, Y. Tsukamoto, S. Tamaki, M. Masuda, K. Okuda, M. Hori, and M. Fukunami Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging Heart, October 1, 2007; 93(10): 1213 - 1218. [Abstract] [Full Text] [PDF]

				P. A. Gould, G. Kong, V. Kalff, S. J. Duffy, A. J. Taylor, M. J. Kelly, and D. M. Kaye Improvement in cardiac adrenergic function post biventricular pacing for heart failure Europace, September 1, 2007; 9(9): 751 - 756. [Abstract] [Full Text] [PDF]

				L. C. Costello-Boerrigter, G. Boerrigter, G. J. Harty, A. Cataliotti, M. M. Redfield, and J. C. Burnett Jr Mineralocorticoid Escape by the Kidney But Not the Heart in Experimental Asymptomatic Left Ventricular Dysfunction Hypertension, September 1, 2007; 50(3): 481 - 488. [Abstract] [Full Text] [PDF]

				M. Kang, K. Y. Chung, and J. W. Walker G-Protein Coupled Receptor Signaling in Myocardium: Not for the Faint of Heart Physiology, June 1, 2007; 22(3): 174 - 184. [Abstract] [Full Text] [PDF]

				G. Guder, J. Bauersachs, S. Frantz, D. Weismann, B. Allolio, G. Ertl, C. E. Angermann, and S. Stork Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure Circulation, April 3, 2007; 115(13): 1754 - 1761. [Abstract] [Full Text] [PDF]

				F. Zannad, E. Huvelle, K. Dickstein, D. J. van Veldhuisen, C. Stellbrink, L. Kober, S. Cazeau, P. Ritter, A. P. Maggioni, R. Ferrari, et al. Left bundle branch block as a risk factor for progression to heart failure Eur J Heart Fail, January 1, 2007; 9(1): 7 - 14. [Abstract] [Full Text] [PDF]

				I. Kovacs, J. Toth, J. Tarjan, and A. Koller Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE Eur J Heart Fail, August 1, 2006; 8(5): 451 - 459. [Abstract] [Full Text] [PDF]

				C. Passino, S. Severino, R. Poletti, M. F. Piepoli, C. Mammini, A. Clerico, A. Gabutti, G. Nassi, and M. Emdin Aerobic Training Decreases B-Type Natriuretic Peptide Expression and Adrenergic Activation in Patients With Heart Failure J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1835 - 1839. [Abstract] [Full Text] [PDF]

				S. Andreas, C. Herrmann-Lingen, T. Raupach, L. Luthje, J. A. Fabricius, N. Hruska, W. Korber, B. Buchner, C-P. Criee, G. Hasenfuss, et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial Eur. Respir. J., May 1, 2006; 27(5): 972 - 979. [Abstract] [Full Text] [PDF]

				P.A. Gould, J. D'Agostino, H.G. Schneider, and D.M. Kaye Influence of atrial fibrillation on cardiac brain natriuretic peptide release during haemodynamic stress in heart failure Eur J Heart Fail, May 1, 2006; 8(3): 263 - 269. [Abstract] [Full Text] [PDF]

				N. S. Dhalla, M. R. Dent, P. S. Tappia, R. Sethi, J. Barta, and R. K. Goyal Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 31 - 45. [Abstract] [PDF]

				M. V. Pitzalis, J. M. Hamlyn, E. Messaggio, M. Iacoviello, C. Forleo, R. Romito, E. de Tommasi, P. Rizzon, G. Bianchi, and P. Manunta Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy Eur J Heart Fail, March 1, 2006; 8(2): 179 - 186. [Abstract] [Full Text] [PDF]

				C. Passino, R. Poletti, F. Bramanti, C. Prontera, A. Clerico, and M. Emdin Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure Eur J Heart Fail, January 1, 2006; 8(1): 46 - 53. [Abstract] [Full Text] [PDF]

				A. Clerico, F. A. Recchia, C. Passino, and M. Emdin Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H17 - H29. [Abstract] [Full Text] [PDF]

				P. A. Gould, M. Yii, M. D. Esler, J. M. Power, and D. M. Kaye Atrial fibrillation impairs cardiac sympathetic response to baroreceptor unloading in congestive heart failure Eur. Heart J., December 1, 2005; 26(23): 2562 - 2567. [Abstract] [Full Text] [PDF]

				S. Andreas, S. D. Anker, P. D. Scanlon, and V. K. Somers Neurohumoral Activation as a Link to Systemic Manifestations of Chronic Lung Disease Chest, November 1, 2005; 128(5): 3618 - 3624. [Abstract] [Full Text] [PDF]

				J.-P. Quenot, G. Le Teuff, C. Quantin, J.-M. Doise, M. Abrahamowicz, D. Masson, and B. Blettery Myocardial Injury in Critically Ill Patients: Relation to Increased Cardiac Troponin I and Hospital Mortality Chest, October 1, 2005; 128(4): 2758 - 2764. [Abstract] [Full Text] [PDF]

				T. Karram, A. Abbasi, S. Keidar, E. Golomb, I. Hochberg, J. Winaver, A. Hoffman, and Z. Abassi Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1351 - H1358. [Abstract] [Full Text] [PDF]

				P. Davidson, G. Paull, D. Rees, J. Daly, and J. Cockburn Activities of Home-Based Heart Failure Nurse Specialists: A Modified Narrative Analysis Am. J. Crit. Care., September 1, 2005; 14(5): 426 - 433. [Abstract] [Full Text] [PDF]

				D. L. Mann and M. R. Bristow Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond Circulation, May 31, 2005; 111(21): 2837 - 2849. [Full Text] [PDF]

				Y. Xu, Z. Zhang, V. Timofeyev, D. Sharma, D. Xu, D. Tuteja, P. H. Dong, G. U. Ahmmed, Y. Ji, G. E Shull, et al. The effects of intracellular Ca2+ on cardiac K+ channel expression and activity: novel insights from genetically altered mice J. Physiol., February 1, 2005; 562(3): 745 - 758. [Abstract] [Full Text] [PDF]

				A. Clerico, M. Emdin, J. P. Goetze, and J. F. Rehfeld Endocrine Paradox in Heart Failure: Resistance to Biological Effects of Cardiac Natriuretic Hormones * Drs. Goetze and Rehfeld respond: Clin. Chem., December 1, 2004; 50(12): 2465 - 2468. [Full Text] [PDF]

				E. Vanoli, S. Bacchini, S. Panigada, F. Pentimalli, and P. B Adamson Experimental models of heart failure Eur. Heart J. Suppl., November 1, 2004; 6(suppl_F): F7 - F15. [Abstract] [Full Text] [PDF]

				M E Onwuamaegbu, M Henein, and A J Coats Cachexia in malaria and heart failure: therapeutic considerations in clinical practice Postgrad. Med. J., November 1, 2004; 80(949): 642 - 649. [Abstract] [Full Text] [PDF]

				P. B. Adamson, A. L. Smith, W. T. Abraham, K. J. Kleckner, R. W. Stadler, A. Shih, M. M. Rhodes, and on behalf of the InSync III Model 8042 and Attain Continuous Autonomic Assessment in Patients With Symptomatic Heart Failure: Prognostic Value of Heart Rate Variability Measured by an Implanted Cardiac Resynchronization Device Circulation, October 19, 2004; 110(16): 2389 - 2394. [Abstract] [Full Text] [PDF]

				P. B. Adamson, W. T. Abraham, C. Love, and D. Reynolds The evolving challenge of chronic heart failure management: A call for a new curriculum for training heart failure specialists J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1354 - 1357. [Abstract] [Full Text] [PDF]

				A. Mano, T. Tatsumi, J. Shiraishi, N. Keira, T. Nomura, M. Takeda, S. Nishikawa, S. Yamanaka, S. Matoba, M. Kobara, et al. Aldosterone Directly Induces Myocyte Apoptosis Through Calcineurin-Dependent Pathways Circulation, July 20, 2004; 110(3): 317 - 323. [Abstract] [Full Text] [PDF]

				S. Schenk, P. M. McCarthy, R. C. Starling, K. J. Hoercher, M. D. Hail, Y. Ootaki, G. S. Francis, K. Doi, J. B. Young, and K. Fukamachi Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy J. Thorac. Cardiovasc. Surg., July 1, 2004; 128(1): 38 - 43. [Abstract] [Full Text] [PDF]

				J. L. Hall, S. Grindle, X. Han, D. Fermin, S. Park, Y. Chen, R. J. Bache, A. Mariash, Z. Guan, S. Ormaza, et al. Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks Physiol Genomics, May 19, 2004; 17(3): 283 - 291. [Abstract] [Full Text] [PDF]

				H. Wang, B. S. Huang, D. Ganten, and F. H.H. Leenen Prevention of Sympathetic and Cardiac Dysfunction After Myocardial Infarction in Transgenic Rats Deficient in Brain Angiotensinogen Circ. Res., April 2, 2004; 94(6): 843 - 849. [Abstract] [Full Text] [PDF]

				F. Hartmann, M. Packer, A. J.S. Coats, M. B. Fowler, H. Krum, P. Mohacsi, J. L. Rouleau, M. Tendera, A. Castaigne, J. Trawinski, et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy Eur J Heart Fail, March 15, 2004; 6(3): 343 - 350. [Abstract] [Full Text] [PDF]

				A. Clerico and M. Emdin Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review Clin. Chem., January 1, 2004; 50(1): 33 - 50. [Abstract] [Full Text] [PDF]

				K. C Wollert and H. Drexler Growth hormone and proinflammatory cytokine activation in heart failure: Just a new verse to an old sirens' song? Eur. Heart J., December 2, 2003; 24(24): 2164 - 2165. [Full Text] [PDF]

				H. R. De Smet, M. F. Menadue, J. R. Oliver, and P. A. Phillips Increased thirst and vasopressin secretion after myocardial infarction in rats Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R1203 - R1211. [Abstract] [Full Text] [PDF]

				P. A Gould, M. D Esler, and D. M Kaye Chronic atrial fibrillation does not influence the magnitude of sympathetic overactivity in patients with heart failure Eur. Heart J., September 2, 2003; 24(18): 1657 - 1662. [Abstract] [Full Text] [PDF]

				C. Meune, J.-J. Mourad, J.-F. Bergmann, and C. Spaulding Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 149 - 154. [Abstract] [PDF]

				M. A. Woo, P. M. Macey, G. C. Fonarow, M. A. Hamilton, and R. M. Harper Regional brain gray matter loss in heart failure J Appl Physiol, August 1, 2003; 95(2): 677 - 684. [Abstract] [Full Text] [PDF]

				A S Androne, K Hryniewicz, R Goldsmith, A Arwady, and S D Katz Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure Heart, August 1, 2003; 89(8): 854 - 858. [Abstract] [Full Text] [PDF]

				P. B. Adamson, K. J. Kleckner, W. L. VanHout, S. Srinivasan, and W. T. Abraham Cardiac Resynchronization Therapy Improves Heart Rate Variability in Patients with Symptomatic Heart Failure Circulation, July 22, 2003; 108(3): 266 - 269. [Abstract] [Full Text] [PDF]

				H. Ruskoaho Cardiac Hormones as Diagnostic Tools in Heart Failure Endocr. Rev., June 1, 2003; 24(3): 341 - 356. [Abstract] [Full Text] [PDF]

				A. P Bolger, A. J.S Coats, and M. A Gatzoulis Congenital heart disease: the original heart failure syndrome Eur. Heart J., May 2, 2003; 24(10): 970 - 976. [Abstract] [Full Text] [PDF]

				T. Reffelmann and R. A. Kloner Cellular cardiomyoplasty--cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure? Cardiovasc Res, May 1, 2003; 58(2): 358 - 368. [Full Text] [PDF]

				S. S. Rathore, J. P. Curtis, Y. Wang, M. R. Bristow, and H. M. Krumholz Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure JAMA, February 19, 2003; 289(7): 871 - 878. [Abstract] [Full Text] [PDF]

				G. Boerrigter, L. C. Costello-Boerrigter, A. Cataliotti, T. Tsuruda, G. J. Harty, H. Lapp, J.-P. Stasch, and J. C. Burnett Jr Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure Circulation, February 11, 2003; 107(5): 686 - 689. [Abstract] [Full Text] [PDF]

				T. Yamada, T. Shimonagata, M. Fukunami, K. Kumagai, H. Ogita, A. Hirata, M. Asai, N. Makino, H. Kioka, H. Kusuoka, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: A prospective study J. Am. Coll. Cardiol., January 15, 2003; 41(2): 231 - 238. [Abstract] [Full Text] [PDF]

				D. J.W. van Kraaij, R. W.M.M. Jansen, F. C.G.J. Sweep, and W. H.L. Hoefnagels Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function Eur J Heart Fail, January 1, 2003; 5(1): 47 - 53. [Abstract] [Full Text] [PDF]

				P. J. Pugh, R. D. Jones, T.H. Jones, and K. S. Channer Heart failure as an inflammatory condition: potential role for androgens as immune modulators Eur J Heart Fail, December 1, 2002; 4(6): 673 - 680. [Abstract] [Full Text] [PDF]

				J. Soler-Soler and D. Garcia-Dorado How to best to counteract the enemies? By blocking neurohormonal activation Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G45 - G50. [Abstract] [PDF]

				P. C. Brum, J. Kosek, A. Patterson, D. Bernstein, and B. Kobilka Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1838 - H1845. [Abstract] [Full Text] [PDF]

				L. Mangin, A. Monti, and C. Medigue Cardiorespiratory system dynamics in chronic heart failure Eur J Heart Fail, October 1, 2002; 4(5): 617 - 625. [Abstract] [Full Text] [PDF]

				F. Ceia, C. Fonseca, T. Mota, H. Morais, F. Matias, A. de Sousa, A. G. Oliveira, and on behalf of the EPICA Investigators Prevalence of chronic heart failure in Southwestern Europe: the EPICA study Eur J Heart Fail, August 1, 2002; 4(4): 531 - 539. [Abstract] [Full Text] [PDF]

				M. R. Shah, V. Hasselblad, S. S. Stinnett, J. M. Kramer, S. Grossman, M. Gheorghiade, K. F. Adams Jr., K. Swedberg, R. M. Califf, and C. M. O'Connor Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure Eur J Heart Fail, June 1, 2002; 4(3): 297 - 304. [Abstract] [Full Text] [PDF]

				A. D. Tiago, D. Badenhorst, D. Skudicky, A. J. Woodiwiss, G. P. Candy, R. Brooksbank, K. Sliwa, P. Sareli, and G. R. Norton An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy Cardiovasc Res, June 1, 2002; 54(3): 584 - 589. [Abstract] [Full Text] [PDF]

				I. S. Anand, V. G. Florea, and L. Fisher Surrogate end points in heart failure J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1414 - 1421. [Abstract] [Full Text] [PDF]

				R Ferrara, F Mastrorilli, G Pasanisi, S Censi, N D'aiello, A Fucili, M Valgimigli, and R Ferrari Neurohormonal modulation in chronic heart failure Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D3 - D11. [Abstract] [PDF]

				G. Malfatto, G. Branzi, B. Riva, L. Sala, G. Leonetti, and M. Facchini Recovery of cardiac autonomic responsiveness with low-intensity physical training in patients with chronic heart failure Eur J Heart Fail, March 1, 2002; 4(2): 159 - 166. [Abstract] [Full Text] [PDF]

				S.-S. Ding, C. Qiu, P. Hess, J.-F. Xi, J.-P. Clozel, and M. Clozel Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure Cardiovasc Res, March 1, 2002; 53(4): 963 - 970. [Abstract] [Full Text] [PDF]

				J. Feenstra, E. R. Heerdink, D. E. Grobbee, and B. H. Ch. Stricker Association of Nonsteroidal Anti-inflammatory Drugs With First Occurrence of Heart Failure and With Relapsing Heart Failure: The Rotterdam Study Arch Intern Med, February 11, 2002; 162(3): 265 - 270. [Abstract] [Full Text] [PDF]

				S. A. Williams, S. V. Kasl, A. Heiat, J. L. Abramson, H. M. Krumholz, and V. Vaccarino Depression and Risk of Heart Failure Among the Elderly: A Prospective Community-Based Study Psychosom Med, January 1, 2002; 64(1): 6 - 12. [Abstract] [Full Text] [PDF]

				J. E. Udelson, W. B. Smith, G. H. Hendrix, C. A. Painchaud, M. Ghazzi, I. Thomas, J. K. Ghali, P. Selaru, F. Chanoine, M. L. Pressler, et al. Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure Circulation, November 13, 2001; 104(20): 2417 - 2423. [Abstract] [Full Text] [PDF]

				P. R Kalra, S. D Anker, and A. J.S Coats Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin Cardiovasc Res, August 15, 2001; 51(3): 495 - 509. [Full Text] [PDF]

				V. Vaccarino, S. V. Kasl, J. Abramson, and H. M. Krumholz Depressive symptoms and risk of functional decline and death in patients with heart failure J. Am. Coll. Cardiol., July 1, 2001; 38(1): 199 - 205. [Abstract] [Full Text] [PDF]

				M. Cicoira, L. Zanolla, A. Rossi, G. Golia, L. Franceschini, G. Cabrini, A. Bonizzato, M. Graziani, S. D. Anker, A. J. S. Coats, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1808 - 1812. [Abstract] [Full Text] [PDF]

				P. B. Adamson and E. Vanoli Early autonomic and repolarization abnormalities contribute to lethal arrhythmias in chronic ischemic heart failure: Characteristics of a novel heart failure model in dogs with postmyocardial infarction left ventricular dysfunction J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1741 - 1748. [Abstract] [Full Text] [PDF]

				D. M. McNamara, R. Holubkov, K. Janosko, A. Palmer, J. J. Wang, G. A. MacGowan, S. Murali, W. D. Rosenblum, B. London, and A. M. Feldman Pharmacogenetic Interactions Between {beta}-Blocker Therapy and the Angiotensin-Converting Enzyme Deletion Polymorphism in Patients With Congestive Heart Failure Circulation, March 27, 2001; 103(12): 1644 - 1648. [Abstract] [Full Text] [PDF]

				T. M. Ramahi, M. D. Longo, A. R. Cadariu, K. Rohlfs, S. A. Carolan, K. M. Engle, H. Samady, and F. J. T. Wackers Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy J. Am. Coll. Cardiol., March 1, 2001; 37(3): 818 - 824. [Abstract] [Full Text] [PDF]

				G. Malfatto, G. Branzi, S. Gritti, L. Sala, R. Bragato, G. B. Perego, G. Leonetti, and M. Facchini Different baseline sympathovagal balance and cardiac autonomic responsiveness in ischemic and non-ischemic congestive heart failure Eur J Heart Fail, March 1, 2001; 3(2): 197 - 202. [Abstract] [Full Text] [PDF]

				J. Galcera-Tomas, F. J. Castillo-Soria, M. Villegas-Garcia, R. Florenciano-Sanchez, J. G. Sanchez-Villanueva, J. A. N. de la Rosa, A. Martinez-Caballero, J. A. Valenti-Aldeguer, P. Jara-Perez, M. Parraga-Ramirez, et al. Effects of Early Use of Atenolol or Captopril on Infarct Size and Ventricular Volume : A Double-Blind Comparison in Patients With Anterior Acute Myocardial Infarction Circulation, February 13, 2001; 103(6): 813 - 819. [Abstract] [Full Text] [PDF]

				M. Gomberg-Maitland, D. A. Baran, and V. Fuster Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist Arch Intern Med, February 12, 2001; 161(3): 342 - 352. [Abstract] [Full Text] [PDF]

				A. P. Maggioni HEART FAILURE: Treatment strategies for heart failure: {beta} blockers and antiarrhythmics Heart, January 1, 2001; 85(1): 97 - 103. [Full Text]

				G. Tjeerdsma, B. M. Szabo, L. M. van Wijk, J. Brouwer, R. A. Tio, H. J.G.M. Crijns, and D. J. van Veldhuisen Autonomic dysfunction in patients with mild heart failure and coronary artery disease and the effects of add-on {beta}-blockade Eur J Heart Fail, January 1, 2001; 3(1): 33 - 39. [Abstract] [Full Text] [PDF]

				A. Khand, I. Gemmel, A. L. Clark, and J. G. F. Cleland Is the prognosis of heart failure improving? J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2284 - 2286. [Full Text] [PDF]

				M. S. Nieminen, J. Akkila, G. Hasenfuss, F. X. Kleber, L. A. Lehtonen, V. Mitrovic, O. Nyquist, W. J. Remme, and on behalf of the Study Group Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1903 - 1912. [Abstract] [Full Text] [PDF]

				K. L. Grady, K. Dracup, G. Kennedy, D. K. Moser, M. Piano, L. W. Stevenson, and J. B. Young Team Management of Patients With Heart Failure : A Statement for Healthcare Professionals From the Cardiovascular Nursing Council of the American Heart Association Circulation, November 7, 2000; 102(19): 2443 - 2456. [Full Text] [PDF]

				M. Araki, K. Hasegawa, E. Iwai-Kanai, M. Fujita, T. Sawamura, T. Kakita, H. Wada, T. Morimoto, and S. Sasayama Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1411 - 1418. [Abstract] [Full Text] [PDF]

				H. L. Hillege, A. R. J. Girbes, P. J. de Kam, F. Boomsma, D. de Zeeuw, A. Charlesworth, J. R. Hampton, and D. J. van Veldhuisen Renal Function, Neurohormonal Activation, and Survival in Patients With Chronic Heart Failure Circulation, July 11, 2000; 102(2): 203 - 210. [Abstract] [Full Text] [PDF]

				D Scrutinio, V Napoli, A Passantino, A Ricci, R Lagioia, and P Rizzon Low-dose dobutamine responsiveness in idiopathic dilated cardiomyopathy: relation to exercise capacity and clinical outcome Eur. Heart J., June 1, 2000; 21(11): 927 - 934. [Abstract] [PDF]

				B. Gremmler, M. Kunert, H. Schleiting, and L.J. Ulbricht Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan Eur J Heart Fail, June 1, 2000; 2(2): 183 - 187. [Abstract] [Full Text] [PDF]

				A. Igawa, T. Nozawa, N. Yoshida, N. Fujii, M. Inoue, S. Tazawa, H. Asanoi, and H. Inoue Heterogeneous cardiac sympathetic innervation in heart failure after myocardial infarction of rats Am J Physiol Heart Circ Physiol, April 1, 2000; 278(4): H1134 - H1141. [Abstract] [Full Text] [PDF]

				T. B. Levine, P. J. L. M. Bernink, A. Caspi, U. Elkayam, E. M. Geltman, B. Greenberg, W. J. McKenna, J. K. Ghali, T. D. Giles, A. Marmor, et al. Effect of Mibefradil, a T-Type Calcium Channel Blocker, on Morbidity and Mortality in Moderate to Severe Congestive Heart Failure : The MACH-1 Study Circulation, February 22, 2000; 101(7): 758 - 764. [Abstract] [Full Text] [PDF]

				Z R Yousef, S R Redwood, and M S Marber Postinfarction left ventricular remodelling: where are the theories and trials leading us? Heart, January 1, 2000; 83(1): 76 - 80. [Full Text] [PDF]

				A. S. Westheim, P. Bostrom, C. C. Christensen, H. Parikka, E. O. Rykke, and L. Toivonen Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure J. Am. Coll. Cardiol., November 15, 1999; 34(6): 1794 - 1801. [Abstract] [Full Text] [PDF]

				R. Ferrari Origin of heart failure: cardiac or generalized myopathy? Eur. Heart J., November 2, 1999; 20(22): 1613 - 1614. [PDF]